Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis

被引:1
|
作者
Tintore, Mar [1 ]
机构
[1] Hosp Univ Vall Hebron, Dept Neurol Neuroimmunol, Ps Vall dHebron,119-129, Barcelona 08035, Spain
关键词
multiple sclerosis; review; Sativex; spasticity; symptom management;
D O I
10.2217/nmt.15.56
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Spasticity is a prevalent and troublesome symptom for people with multiple sclerosis (MS). Common instruments to measure MS spasticity include the clinician-rated (modified) Ashworth scale and the patient-rated 0-10 spasticity Numerical Rating Scale (NRS). Current opinion is that measurement of MS spasticity should incorporate the patient's perspective. Other instruments to assess spasticity-associated symptoms such as the Penn spasms frequency scale, sleep quality NRS and pain NRS can assist in tracking MS spasticity evolution and inform management choices. Worsening spasticity reduces patient autonomy, impacts negatively on quality of life and increases health resource utilization and costs. Despite the wide range of issues associated with MS spasticity, undertreatment is common and standard treatment options (physiotherapy and classical oral therapies) often fail to provide adequate symptomatic control.
引用
收藏
页码:15 / 17
页数:3
相关论文
共 50 条
  • [31] Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis
    Novarella, F.
    Carotenuto, A.
    Cipullo, P.
    Iodice, R.
    Cassano, E.
    Spiezia, A.
    Capasso, N.
    Petracca, M.
    Falco, F.
    Iacovazzo, C.
    Servillo, G.
    Lanzillo, R.
    Morra, V. Brescia
    Moccia, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 642 - 642
  • [32] Advances in multiple sclerosis
    Berressem, P
    CHEMISTRY IN BRITAIN, 1999, 35 (08) : 33 - 36
  • [33] Advances in Multiple Sclerosis
    Rivera, Victor M.
    BIOMEDICINES, 2025, 13 (02)
  • [34] Advances in multiple sclerosis
    Berressem, Paul
    Chemistry in Britain, 35 (08):
  • [35] Multiple sclerosis: pathophysiology revisited
    Sorensen, PS
    LANCET NEUROLOGY, 2005, 4 (01): : 9 - 10
  • [36] Seizures in Patients with Multiple Sclerosis Epidemiology, Pathophysiology and Management
    Kelley, Brendan J.
    Rodriguez, Moses
    CNS DRUGS, 2009, 23 (10) : 805 - 815
  • [37] Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice
    Pozzilli, Carlo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 49 - 54
  • [38] PATHOPHYSIOLOGY IN MULTIPLE-SCLEROSIS
    MCDONALD, WI
    BRAIN, 1974, 97 (MAR) : 179 - 196
  • [39] Neurovegetative symptoms in assessment of depression in Multiple Sclerosis
    Beeney, J.
    Arnett, P. A.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2007, 22 (07) : 889 - 889
  • [40] Levetiracetam for phasic spasticity in multiple sclerosis
    Hawker, K
    Frohman, E
    Racke, M
    ARCHIVES OF NEUROLOGY, 2003, 60 (12) : 1772 - 1774